Bladder cancer is a global health issue with sex differences in incidence and prognosis.
Bladder cancer has distinct molecular subtypes with multiple pathogenic pathways …

Over the past 5 years, improvements in the design of antibody–drug conjugates (ADCs)
have enabled major advances that have reshaped the treatment of several advanced-stage …

Background No treatment has surpassed platinum-based chemotherapy in improving
overall survival in patients with previously untreated locally advanced or metastatic …

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate
the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing …

PURPOSE Patients with locally advanced or metastatic urothelial cancer (la/mUC) who are
ineligible for cisplatin-based therapy have limited first-line (1L) treatment options and …

Purpose: The antibody–drug conjugate enfortumab vedotin (EV) releases a cytotoxic agent
into tumor cells via binding to the membrane receptor NECTIN-4. EV was recently approved …

Simple Summary Antibody–drug conjugates (ADC) have shown remarkable therapeutic
activity in a wide range of hematologic and solid tumors. Herein, we discuss the …

Antibody-drug conjugates (ADCs) represent an important class of cancer therapies that have
revolutionized the treatment paradigm of solid tumors. To date, many ongoing studies of …

Context Several recent phase 2 and 3 trials have evaluated the efficacy and toxicity of
checkpoint inhibitor (CPI) therapy for urothelial carcinoma (UC) in the metastatic, localized …

Bladder cancer remains a leading cause of cancer death worldwide and is associated with
substantial impacts on patient quality of life, morbidity, mortality, and cost to the healthcare …